bird-flu-stocks-logo
birdflustocks.com
CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study
birdflustocks.com » bird flu stocks  »  CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study
CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study
April 4, 2024
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK